top of page

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Updated: 2 days ago

ree

Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a set of regulatory and clinical milestones that together mark our first commercial entry into U.S. eye care and limbal stem cells (“LSC”) exosome-based therapeutics. Through our partner 3D Global Biotech Inc. (“3D Global Biotech”), Exovisse Contact Lenses have obtained FDA 510(k) clearance as a Class II medical device, enabling legal marketing in the United States. In parallel, our Exovisse Artificial Tears have been developed in compliance with the FDA OTC Final Monograph M018, permitting nationwide over-the-counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval, and our LSC and LSC-derived exosomes have been enrolled in the FDA Drug Master File.


In plain terms, 510(k) clearance confirms the lenses are substantially equivalent to an already marketed device and can be sold in the U.S., while OTC monograph compliance confirms the artificial tears meet established safety and labeling requirements and can be marketed without case-by-case approval. For consumers, that means easier access to trusted solutions for comfort and clearer vision, which establishes a commercial foundation for YD Bio in ophthalmology that complements ongoing clinical development.


YD Bio and 3D Global Biotech are also planning a small clinical trial in Taiwan to evaluate dry eye disease, working with YC Biotech, a Taiwan-based contract research organization. The Company is simultaneously advancing LSC Exosome Therapeutics through active collaboration with 3D Global Biotech, pursuing limbal stem cell–derived exosome applications via injection and eye drops for retinal and macular disorders. YD Bio has enrolled its limbal stem cells and limbal stem cell exosomes in the FDA Drug Master File, establishing quality and regulatory documentation to support future therapeutic development.


“Together, these achievements demonstrate YD Bio’s transition from laboratory innovation to patient-ready products, while building a pipeline aimed at novel therapies for serious eye conditions,” Dr. Ethan Shen, Chairman and CEO of the Company, commented. “We are starting to make our everyday eye care products available in the U.S., which signals a pragmatic path from development to revenue within a large, needs-based category.”


Development timelines and commercial outcomes may be affected by factors including technology evolution, clinical validation, regulatory feedback, partner execution, customer acceptance, competitive dynamics, and macroeconomic conditions. We will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.


About YD Bio Limited

YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com


Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, our business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions.


We undertake no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in our expectations, except as may be required by law. Although we believe that the expectations expressed in these forward-looking statements are reasonable, we cannot assure you that such expectations will turn out to be correct, and we caution investors that actual results may differ materially from the anticipated results and encourage investors to review other factors that may affect our future results in our registration statement and other filings with the U.S. Securities and Exchange Commission.


For investor and media inquiries, please contact:

YD Bio Limited Investor Relations


WFS Investor Relations Inc.

Phone: +1 628 283 9214



Selected Media Coverage

This announcement has been picked up by major financial and business outlets, including:

It has also been republished by industry journals and regional healthcare media, such as:

In Taiwan, the news has also been covered by local media, including:

bottom of page